The **Scientific and Educational Interaction Day (SEID)** is an exciting meeting which boasts educational lectures focused mainly on clinical issues, starting from diagnosis all the way to prevention and therapy. Sessions will focus on systemic diseases that affect the kidney (ANCA-associated vasculitis, lupus nephritis, anti-GBM disease), ethical aspects of using genetic results in clinical daily practice and its implications but also stimulating discussions on patients and nephrologists' considerations on the choice among hemodialysis, peritoneal dialysis and transplantation, being the latter considered the best treatment option for ESKD, as well. A consistent part of the meeting is devoted to **vascular access** which includes

A consistent part of the meeting is devoted to **vascular access** which includes a **practical session involving demonstrations of ultrasound scanning and fistula imaging on real patients**. All participants will have a chance to practise imaging under the supervision and guidance of experts.

The SEID has multiple educational objectives. It gives you the chance to learn how to responsibly apply genetic testing; it provides updates of current approaches to the diagnosis and treatment of systemic diseases and shares data on ongoing studies and emerging treatment options. It discusses the possibilities to better predict patient survival depending on recipient characteristics (comorbidities) as well as donor quality scores (such as KDRI). All of this in one single event!

Do not miss the Satellite 'New Drug' Symposium which is preceding the SEID on October 25. This half-day symposium is designed to be a fully educational experience with some 'industry focus': key European speakers will contribute in the sessions providing updates on recent studies related to the treatment of anaemia, hyperkalaemia and diabetes in CKD.

Sessions will be available after the event as e-materials.

How to register ERA-EDTA Members only (categories A and B) are entitled to participate in the meetings (October 25-26). Admittance fee is EUR 175,00.

Travel grant opportunities - The ERA-EDTA offers up to a max. amount of **EUR 30,000.00 in Travel Grants** to **ERA-EDTA members** (categories A and B) **who are not older than 40** in 2019. For information and applications please contact: **seid@era-edta.org**.

For information please contact:


ERA-EDTA Group seid@era-edta.org



organisation@era-edta.org Phone: +39 0521 989078

www.era-edta.org









Scientific and Educational Interaction Day

October 26, 201

NAME ATTACK

Preceded by its Satellite 'New Drug Symposium' October 25, 2019 14.00-17.30

Vienna Hilton Danube Waterfront Grandwaterfront Hall 1-2-3 Vienna, Austria

October 25, 2019 New Drug Symposium

15.00-16.00	Renal anemia and HIF
	SGLT2-inhibition in non-diabetic CKD Johannes Mann, Munich, Germany
	SGLT2-inhibition in diabetic CKD Gert Mayer , Innsbruck, Austria
14.00-15.00	SGLT2 in diabetic and non-diabe
13.00-14.00	Lunch

Intravenous iron for treatment of anemia in CKD **Lucia Del Vecchio**, Lecco, Milan

betic CKD

HIF stabilizers for treatment of anemia in CKD **Kai Uwe Eckardt**, Berlin, Germany

16.00-16.30 Break

16.30-17.30 RAAS and Hyperkalemia

The risk of hyperkaliemia in CKD and in heart failure **Marie Evans**, Stockholm, Sweden

New options for hyperkalemia treatment **Giovambattista Capasso**, Naples, Italy



October 26, 2019

Scientific and Educational Interaction Day

8.30-10.00	Session 1 - Ethical aspects of genetic testing in kidney diseases Ethical aspects of using genetic results for clinical decision making Albertien van Eerde, Utrecht, The Netherlands Presymptomatic testing in ADPKD Tess Harris, London, United Kingdom Genomic testing as part of mainstream nephrology; lessons for practicing nephrologists Daniel Gale, London, United Kingdom
10.00-10.30	Break
10.30-12.00	Session 2 - Systemic diseases affecting the kidney Extrarenal involvement in SLE and its impact on the outcome of pts with LN Vladimir Tesar, Prague, Czech Republic Renal involvement in AAV and its treatment Annette Bruchfeld, Stockholm, Sweden Anti-GBM disease with and without lung hemorrhage Marten Segelmark, Lund, Sweden
12.00-13.15	Lunch
13.15-14.45	Session 3 - Is transplantation the best option in this patient with this donor kidney? Barriers for patients and nephrologists with respect to RRT modality choice Vianda Stel, Amsterdam, The Netherlands

Older donor kidneys: how well do they really function and who should receive them?

Maria Pippias, Amsterdam, The Netherlands

Is there always a survival benefit with transplantation? **Rachel Hellemans**, Antwerp, Belgium

14.45-15.15 Break

15.15-18.00 Session 4 - Vascular access: the practicalities of fistula imaging

Brief introduction: ultrasound scanning in the context of fistulae **Karen Stevenson**, Glasgow, United Kingdom Practical demonstration of fistula imaging

Jose Ibeas, Barcelona, Spain

This session includes a practical section involving demonstrations of ultrasound scanning and fistula imaging on real patients. All participants will have a chance to practise imaging under the supervision and guidance of experts.